Biotechnology - Teva Pharmaceutical Industries

Filter

Popular Filters

Israel's Clal Biotech in talks to sell Andromeda unit

28-02-2014

In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February…

Andromeda BiotechBiotechnologyClal BiotechnologyDiabetesDiaPep277Mergers & AcquisitionsTeva Pharmaceutical Industries

Gilead and Teva settle Viread patent litigation

20-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Teva pulls out of CureTech deal; AC Immune drops CI-91

01-02-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration…

AC ImmuneBiotechnologyCT-011CureTechLicensingNeurologicalOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Galena Biopharma leaps on deal with Teva for NeuVax in Israel

05-12-2012

Shares of US biotech firm Galena Biopharma (Nasdaq: GALE) leapt 13.7% to $2.32 in pre-market trading…

BiotechnologyGalena BioPharmaLicensingnelipepimut-SNeuVaxOncologyRest of the WorldTeva Pharmaceutical IndustriesVaccines

Novogen to acquire Triaxial Pharma for $1.8 million; EU approves Teva/P&G deal

13-11-2012

Biotechnology firm Novogen (ASX: NRT) yesterday announced that it has signed a term sheet in relation…

BiotechnologyMergers & AcquisitionsNovogenPharmaceuticalProcter & GambleRegulationTeva Pharmaceutical IndustriesTriaxial Pharmaceuticals

M&A briefs: GlaxoSmithKline/Response Genetics; Bayer/Teva unit

16-09-2012

USA-based Response Genetics (Nasdaq: RGDX) last week entered into a purchase agreement with UK pharma…

BayerBiotechnologyFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalResponse GeneticsTeva Pharmaceutical Industries

FDA approves pediatric Afinitor from Novartis and Teva's tbo-filgrastim

30-08-2012

The US Food and Drug Administration yesterday approved Swiss drug major Novartis' (NOVN: VX) Afinitor…

AfinitorBiotechnologyGenericsNorth AmericaNovartisOncologyPharmaceuticalRegulationSicor Biotechtbo-filgrastimTeva Pharmaceutical Industries

Teva and OncoGenex update on prostate cancer drug development; loss widens at latter

12-03-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) and US/Canadian partner OncoGenex Pharmaceuticals…

BiotechnologycustirsenFinancialLicensingOncoGenexPharmaceuticalResearchTeva Pharmaceutical Industries

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint

22-11-2011

Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst

24-10-2011

Following the September 2010 US launch, Swiss drug major Novartis’ (NOVN: VX) first-in-class, once-daily…

AubagioBiogen IdecBiotechnologyGilenyalaquinimodLemtradaMarkets & MarketingNeurologicalNovartisocrelizumabPharmaceuticalResearchRocheSanofiTeva Pharmaceutical Industries

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon

24-10-2011

As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Back to top